Harmonizing Standards and Incentives in Medical Device Regulation: Lessons Learned from the Parallel Review Pathway

Centers for Medicare and Medicaid Services & Food and Drug Administration. Parallel review of medical products, available at <https://www.federalregister.gov/documents/2010/09/17/2010-23252/parallel-review-of-medical-products> (last accessed November 27, 2018.

D.B. Kramer , S. Xu , and A.S. Kesselheim , “Regulation of Medical Devices in the United States and European Union,” New England Journal of Medicine 366, no. 9 (2012): 848-855.

US Food and Drug Administration, Premarket Application Review Process, available at <https://www.fda.gov/MedicalDevices/DeviceRegulationand-Guidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm047991.htm> (last accessed November 27, 2018).

U.S. FDA. Code of Federal Regulations. Title 21, Volume 8, Chapter I, Subchapter H, Part 860, available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?FR=860.7> (last visited November 27, 2018).

S.S. Dhruva , L.A. Bero , and R.F. Redberg , “Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices,” JAMA 302, no. 24 (2009): 2679-2685; V.K. Rathi, H.M. Krumholz, and F.A. Masoudi, J.S. Ross, “Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011,” JAMA 314, no. 6 (2015):604-612.

J.D. Chambers , K.E. May , and P.J. Neumann , “Medicare Covers the Majority of FDA-Approved Devices and Part B Drugs, but Restrictions and Discrepancies Remain,” Health Affairs (Mill-wood) 32, no. 6 (2013):1109-1115.

S. Tunis , R. Berenson , S. Phurrough , and P. Mohr , “Improving the Quality and Efficiency of the Medicare Program through Coverage Policy Issues,” Urban Institute (2011), available at <http://www.urban.org/sites/default/files/alfresco/publication-pdfs/412392-Improving-the-Quality-and-Efficiency-of-the-Medicare-Program-Through-Coverage-Policy.PDF> (last accessed November 27, 2018); P.J. Neumann and J.D. Chambers, “Medicare’s Enduring Struggle to Define ‘Reasonable and Necessary’ Care, New England Journal of Medicine 367, no. 19 (2012): 1775-1777.

Centers for Medicare and Medicaid Services. Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4), available at <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=263> (last accessed November 27, 2018).

Department of Health and Human Services, “Local Coverage Determinations Create Inconsistency in Medicare Coverage,” available at <https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf> (last accessed November 27, 2018).

114th Congress. Public Law 114-255. 21st Century Cures Act. (last accessed August 30, 2018).

P.J. Neumann , M.S. Kamae , and J.A. Palmer , “Medicare’s National Coverage Decisions for Technologies, 1999-2007, Health Affairs (Millwood) 27, no. 6 (2008):1620-1631.

Center for Medicaid and Medicare Services. Coverage with evidence development, available at <https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/> (last accessed November 27, 2018); see Tunis, supra note 7.

Centers for Medicare and Medicaid Services, Guidance for the Public, Industry, and CMS Staff: Coverage with Evidence Development, available at <https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=27> (last accessed November 27, 2018).

M.W. Krucoff , R.G. Brindis , P.K. Hodgson , Mj.J. Mack , and D.R. Holmes, Jr., “Medical Device Innovation: Prospective Solutions for an Ecosystem in Crisis. Adding a Professional Society Perspective,” JACC: Cardiovascular Interventions 5, no. 7 (2012):790-796; R.A. Lindor, S.J. Allocco, L. Cheatham, et al. “Regulatory and Reimbursement Innovation,” Science Translational Medicine 5, no. 176 (2013):176cm3.

D.A. Messner and S.R. Tunis , “Current and Future State of FDA-CMS Parallel Reviews, Clinical Pharmacology & Therapeutics 91, no. 3 (2012): 383-385.

J.R. Ridge and S. Statz , “Exact Sciences’ Experience with the FDA and CMS Parallel Review Program,” Expert Review of Molecular Diagnostics 15, no. 9 (2015):1117-1124.

Centers for Medicare and Medicaid Services, Medicare Program Integrity Manual – Chapter 13 Local Coverage Determinations, available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/…/pim83c13.pdf> (last accessed November 27, 2018).

Memorandum of Understanding between United States Food and Drug Administration and Centers for Medicare & Medicaid Services In: Administration FaD, ed.2010.

Pilot Program for Parallel Review of Medical Products In: Administration CfMaMSFaD, ed.2011:62808-10; Services DoHaH. Medicare Program: Revised Process for Making National Coverage Determinations. In: Services CfMM, ed. Federal Register2003:55634-41.

Chambers, supra note 6; S. Basu and J.C. Hassenplug , “Patient Access to Medical Devices — A Comparison of U.S. and European Review Processes,” New England Journal of Medicine 367, no. 6 (2012):485-488.

J.D. Chambers , M. Chenoweth , T. Thorat , and P.J. Neumann , “Private Payers Disagree with Medicare over Medical Device Coverage about Half the Time,” Health Affairs (Millwood) 34, no. 8 (2015):1376-1382.

D.E. Forman , M.S. Maurer , C. Boyd , et al., “Multimorbidity in Older Adults With Cardiovascular Disease,” Journal of the American College of Cardiology 71, no. 19 (2018): 2149-2161.

S.S. Dhruva , C.M. Mazure , J.S. Ross , R.F. Redberg , “Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices,” JAMA Internal Medicine 177, no. 9 (2017):1390-1391.

National Academies of Sciences, Engineering, and Medicine, “Strategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials,” (Washington, DC: National Academies Press, August 24, 2016), available at <https://www.ncbi.nlm.nih.gov/pubmed/27606381> (last accessed November 27, 2018); US Food and Drug Administration, “FDA Report: Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products,” August 2013, available at <https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/UCM365544.pdf> (last accessed November 27, 2018).

E. Richardson , “Health Policy Brief: Aligning FDA and CMS Review,” Health Affairs (2015), available at <https://www.healthaffairs.org/do/10.1377/hpb20150827.132391/full/> (last accessed December 12, 2018); F. Zannad, M.L.A. Alonso Garcia, and J.S. Borer, et al. “Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement,” Journal of the American College of Cardiology 70, no. 22 (2017):2822-2830.

J. Rickard , H. Michtalik , R. Sharma , et al., “Use of Cardiac Resynchronization Therapy in the Medicare Population,” AHRQ Technology Assessment, Rockville, MD, 2015.

D.B. Kramer and D.A. Steinhaus , “Cardiac Resynchronization Therapy in Older Patients: Age Is Just a Number, and Yet…,” Journal of Cardiac Failure 22, no. 12 (2016): 978-980; M.B. Elming, J.C. Nielsen, J. Haarbo, et al., “Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure,” Circulation 136, no. 19 (2017):1772-1780.

US Food and Drug Administration, Medical Devices: Databases, 510(k) premarket notification, available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> (last acessed November 27, 2018).

Institute of Medicine, Medical Devices and the Public’s Health: The FDA 510(k) Clearance Process at 35 Years, Washington, DC: National Academies Press, 2011; B.M. Ardaugh, S.E. Graves, and R.F. Redberg, “The 510(k) Ancestry of a Metal-on-Metal Hip Implant,” New England Journal of Medicine 368, no. 2 (2013): 97-100.

See Chambers, supra note 6.

Forman, supra note 22.

S.S. Dhruva and R.F. Redberg , “Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence used for Medicare National Coverage Decisions,” Archives of Internal Medicine 168, no. 2 (2008):136-140.

M. Tisminetzky , E.A. Bayliss , J.S. Magaziner , et al., “Research Priorities to Advance the Health and Health Care of Older Adults with Multiple Chronic Conditions,” Journal of the American Geriatrics Society 65, no. 7 (2017):1549-1553; A.S. Bierman and M.E. Tinetti, “Precision Medicine to Precision Care: Managing Multimorbidity, Lancet 388, no. 10061 (issue number?)(2016): 2721-2723.

Department of Health and Human Services, Office of Inspector General, Local Coverage Determinations Create Inconsistency in Medicare Coverage, OEI-01-11-00500, January 2014.

Centers for Medicare and Medicaid Services, Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4), available at <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=263> (last acessed November 27, 2018).

Centers for Medicare and Medicaid Services, Decision Memo for Transcatheter Aortic Valve Replacement (CAG-00430N), available at <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=257&ver=4&NcaName=Transcatheter+Aortic+Valve+Replacement+(TAVR)&bc=ACAAAAAAIAAA&> (last acessed November 27, 2018).